Author

Boryana Ivanova

Observed name: B. Ivanova

Institution: Medical University of Sofia

Observed institutions: Medical University of Sofia, Pathologisches Institut, Ludwig-Maximilians-Universität München

ORCID: 0000-0003-2466-9254

Observed ORCID: 0000-0003-2466-9254

OpenAlex ID: A5048018717

Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2020 · Arndt Stahler, Sebastian Stintzing, et al. · Clinical Cancer Research · 26

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial

2018 · Sebastian Stintzing, Boryana Ivanova, et al. · Frontiers in Oncology · 23

Real-world effectiveness of Ruxolitinib: analysis and comparison with COMFORT-II

2026 · Antoan Rangelov, Boryana Ivanova, et al. · Pharmacia · 1

Real-World Evidence of Atezolizumab Efficacy as Part of First-Line Treatment for Extensive-Stage SCLC in Bulgaria

2026 · Manoela Manova, Boryana Ivanova, et al. · Cancers · 1

EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia

2025 · Magdalena Monica, Sabina Becirovic, et al. · Frontiers in Pharmacology · 1

Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis

2025 · Manoela Manova, Boryana Ivanova, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 1

Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice

2024 · Alexandra Savova, Boryana Ivanova, et al. · Pharmacia · 1

Enzalutamide Plus ADT for the Treatment of mHSPC: Real-World Evidence from a Bulgarian Cohort

2026 · Manoela Manova, Boryana Ivanova, et al. · Cancers

Effectiveness of ribociclib in metastatic breast cancer in one hospital in Bulgaria—results from real-world clinical practice

2026 · Mariyana Eneva, Petya Borisova, et al. · Pharmacia

RWD121 Real World PFS Outcomes of Bulgarian Patients With BRAF-Positive Melanoma Treated With Dabrafenib and Trametinib

2024 · B. Ivanova, A. Savova, et al. · Value in Health

eFigure 1 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eTable 4 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eTable 3 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eTable 2 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eTable 1 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eFigure 2 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eFigure 4 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eFigure 3 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

Data from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

Data from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eTable 4 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eTable 1 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

eTable 2 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

2023 · Arndt Stahler, Sebastian Stintzing, et al.

High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.

2020 · Arndt Stahler, Sebastian Stintzing, et al. · Journal of Clinical Oncology

Works count: 24

Citation count: 54

H-index: 2

I10-index: 2